199 related articles for article (PubMed ID: 36077197)
1. Serum Ceramide Species Are Associated with Liver Cirrhosis and Viral Genotype in Patients with Hepatitis C Infection.
Höring M; Peschel G; Grimm J; Krautbauer S; Müller M; Weigand K; Liebisch G; Buechler C
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077197
[TBL] [Abstract][Full Text] [Related]
2. Gender-Specific Differences in Serum Sphingomyelin Species in Patients with Hepatitis C Virus Infection-Sphingomyelin Species Are Related to the Model of End-Stage Liver Disease (MELD) Score in Male Patients.
Peschel G; Weigand K; Grimm J; Müller M; Krautbauer S; Höring M; Liebisch G; Buechler C
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176109
[TBL] [Abstract][Full Text] [Related]
3. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
4. Sex-specific changes in triglyceride profiles in liver cirrhosis and hepatitis C virus infection.
Peschel G; Grimm J; Müller M; Höring M; Krautbauer S; Weigand K; Liebisch G; Buechler C
Lipids Health Dis; 2022 Oct; 21(1):106. PubMed ID: 36280840
[TBL] [Abstract][Full Text] [Related]
5. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
[TBL] [Abstract][Full Text] [Related]
7. Serum Galectin-3 in Hepatitis C Virus Infection Declines after Successful Virus Eradication by Direct-Acting Antiviral Therapy.
Weigand K; Peschel G; Grimm J; Müller M; Buechler C
J Gastrointestin Liver Dis; 2022 Dec; 31(4):444-452. PubMed ID: 36535063
[TBL] [Abstract][Full Text] [Related]
8. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
9. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
10. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
11. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
[TBL] [Abstract][Full Text] [Related]
12. Protein Tyrosine Phosphatase Nonreceptor Type 2 Expression Does Not Correlate with Viral Load or Response to Direct-Acting Antiviral Therapy in Hepatitis C Virus Infections-Infected Patients.
Sabev M; Blümel S; Lang S; Gottier C; Weber A; Mertens J; Müllhaupt B; Scharl M; Spalinger MR
Digestion; 2021; 102(3):453-461. PubMed ID: 32074607
[TBL] [Abstract][Full Text] [Related]
13. Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy.
Grimm J; Peschel G; Müller M; Schacherer D; Wiest R; Weigand K; Buechler C
J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33920491
[TBL] [Abstract][Full Text] [Related]
14. Relationship between genotypes of hepatitis C virus and histopathological manifestations in chronic hepatitis C patients.
Adinolfi LE; Utili R; Andreana A; Tripodi MF; Rosario P; Mormone G; Ragone E; Pasquale G; Ruggiero G
Eur J Gastroenterol Hepatol; 2000 Mar; 12(3):299-304. PubMed ID: 10750650
[TBL] [Abstract][Full Text] [Related]
15. Elevated plasma sphingomyelin (d18:1/22:0) is closely related to hepatic steatosis in patients with chronic hepatitis C virus infection.
Li JF; Qu F; Zheng SJ; Wu HL; Liu M; Liu S; Ren Y; Ren F; Chen Y; Duan ZP; Zhang JL
Eur J Clin Microbiol Infect Dis; 2014 Oct; 33(10):1725-32. PubMed ID: 24810965
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers.
Sandmann L; Dörge P; Wranke A; Vermehren J; Welzel TM; Berg CP; Grottenthaler JM; Weiss KH; Langel J; Sterneck M; von Wulffen M; Manns MP; Wedemeyer H; Hardtke S; von Hahn T
Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1049-1056. PubMed ID: 30807443
[TBL] [Abstract][Full Text] [Related]
17. Rising Lysophosphatidylcholine Levels Post-Hepatitis C Clearance.
Peschel G; Krautbauer S; Weigand K; Grimm J; Höring M; Liebisch G; Müller M; Buechler C
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256273
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges.
Ekpanyapong S; Reddy KR
United European Gastroenterol J; 2019 Jun; 7(5):642-650. PubMed ID: 31210942
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.
Janczewska E; Kołek MF; Lorenc B; Klapaczyński J; Tudrujek-Zdunek M; Sitko M; Mazur W; Zarębska-Michaluk D; Buczyńska I; Dybowska D; Czauż-Andrzejuk A; Berak H; Krygier R; Jaroszewicz J; Citko J; Piekarska A; Dobracka B; Socha Ł; Deroń Z; Laurans Ł; Białkowska-Warzecha J; Tronina O; Adamek B; Tomasiewicz K; Simon K; Pawłowska M; Halota W; Flisiak R
World J Gastroenterol; 2021 May; 27(18):2177-2192. PubMed ID: 34025072
[TBL] [Abstract][Full Text] [Related]
20. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Tada T; Kurosaki M; Nakamura S; Hasebe C; Kojima Y; Furuta K; Kobashi H; Kimura H; Ogawa C; Yagisawa H; Uchida Y; Joko K; Akahane T; Arai H; Marusawa H; Narita R; Ide Y; Sato T; Kusakabe A; Tsuji K; Mori N; Kondo M; Mitsuda A; Izumi N
J Med Virol; 2021 Nov; 93(11):6247-6256. PubMed ID: 34170517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
